<SEC-DOCUMENT>0001140361-23-008862.txt : 20230227
<SEC-HEADER>0001140361-23-008862.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227160527
ACCESSION NUMBER:		0001140361-23-008862
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		23674720

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>brhc10048924_dfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160;</div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">SCHEDULE 14A</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Proxy Statement Pursuant to Section 14(a) of the</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Securities Exchange Act of 1934</div>
    <div>&#160;</div>
    <div style="text-indent: -9pt; margin-left: 9pt;">Filed by the Registrant &#9744;</div>
    <div style="text-indent: -9pt; margin-left: 9pt;">&#160;</div>
    <div style="text-indent: -9pt; margin-left: 9pt;">Filed by a party other than the Registrant&#8194;&#9746;</div>
    <div>&#160;</div>
    <div>Check the appropriate box:</div>
    <table cellspacing="0" cellpadding="0" id="zbda51b35231e49f29b1e0a81a5d9dfac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; vertical-align: top;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Preliminary Proxy Statement</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z819aa67f9ca440b89d80d8fbcfe91a79" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; vertical-align: top;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z0adea44d82a6482f8caeceaaf1d4cbf2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; vertical-align: top;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Definitive Proxy Statement</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z3b3cc1763936473483c7e023d464b26d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; vertical-align: top;">&#9746;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Definitive Additional Materials</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z5fd1283f111e477f9d9b5b582fa21aab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; vertical-align: top;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Soliciting Material under &#167; 240.14a-12</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">Amarin Corporation plc</div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div>
      <div style="text-align: center;">(Name of Registrant as Specified In Its Charter)</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Catapult Fund LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Hawkeye Fund LP</div>
    <div style="text-align: center; font-weight: bold;">ISP Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Master Fund II LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Athena Fund Ltd</div>
    <div style="text-align: center; font-weight: bold;">Atom Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management LP</div>
    <div style="text-align: center; font-weight: bold;">Alexander J. Denner, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">Patrice Bonfiglio</div>
    <div style="text-align: center; font-weight: bold;">Paul Cohen, M.D.</div>
    <div style="text-align: center; font-weight: bold;">Mark DiPaolo</div>
    <div style="text-align: center; font-weight: bold;">Keith L. Horn</div>
    <div style="text-align: center; font-weight: bold;">Odysseas Kostas, M.D.</div>
    <div style="text-align: center; font-weight: bold;">Louis Sterling III</div>
    <div style="text-align: center; font-weight: bold;">Diane E. Sullivan</div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>
      <div style="text-align: center;">&#160;(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
      <div>&#160;</div>
    </div>
    <div>Payment of Filing Fee (Check all boxes that apply):</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z998b1a0f6330478f852a7422e2c9912d" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#9746;</div>
            </td>
            <td style="vertical-align: bottom; width: auto; text-align: left;">
              <div>No fee required</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za8f44fa77b9f4760b9a0d02e225cb6c3" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#9744;</div>
            </td>
            <td style="vertical-align: bottom; width: auto; text-align: left;">
              <div>Fee paid previously with preliminary materials</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z61c89ff0a01b4d4787310fd1f2073c1d" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#9744;</div>
            </td>
            <td style="vertical-align: bottom; width: auto; text-align: left;">
              <div>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>This filing contains a press release issued on February 27, 2023 by Sarissa Capital.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">SARISSA CAPITAL CONDEMNS AMARIN BOARD FOR FRONTRUNNING RESULTS OF PROXY CONTEST WITH EGREGIOUS EQUITY GRANTS TO EXECUTIVES</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Sarissa believes Amarin board acted in bad faith by making these equity grants while refusing to disclose proxy contest results and will hold each director personally accountable</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Sarissa urges Amarin CEO Karim Mikhail to repudiate his undeserved equity grants and re-issue them to hard working Amarin employees</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Greenwich, CT, February 27, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):</div>
      <div><br>
      </div>
      <div>Sarissa is appalled at this latest act of betrayal of the shareholders by the Amarin board. Sarissa has been urging the Amarin board to release the results of the proxy contest for several days.&#160; The board, however, has steadfastly refused,
        leaving Amarin shareholders to twist in the wind. Now we know why the board has opted to sit on this powder keg of information. Late last week in the stealth of night and right before the General Meeting, the Amarin board disclosed egregious equity
        grants to executives representing more than 3.6 million shares. CEO Karim Mikhail was given 70% more in equity grants than last year despite the horrendous performance of the company under his leadership. If that is not enough, apparently these
        grants vest solely based on the passage of time with absolutely no performance criteria.</div>
      <div><br>
      </div>
      <div>It is important to note that the board did not make these grants consistent with last year&#8217;s timing but instead made them several weeks later than usual and with no disclosure of any kind in its proxy materials. In so doing, the board ensured
        that it would not have to disclose this betrayal of shareholders until after the voting deadline in this proxy contest had passed.</div>
      <div><br>
      </div>
      <div>By making these equity grants in this manner, we believe the board acted in bad faith and engaged in numerous breaches of its fiduciary duties and violations of law. How can a properly functioning board that is abiding by its duties make these
        grants right before a contested election that could dramatically alter the composition of the board, after the voting deadline has passed, and with no prior disclosure? Bear in mind that at last year&#8217;s annual meeting more than a majority of the
        outstanding stock either abstained or voted against &#8220;Say on Pay,&#8221; yet this board determines to change the timing of and significantly increase the quantum of executive equity grants. We believe the answer is simple &#8212; this board is violating its
        fiduciary duties and applicable law. Accordingly, we intend to hold each director personally liable to the fullest extent permissible under applicable law.</div>
      <div><br>
      </div>
      <div>Karim, last week you sent a self-serving letter to employees in which you thanked all employees for their hard work. Now is the perfect time for you to put your money where your mouth is. Prior equity grants to these employees have been
        significantly impaired by the incompetence of the Amarin board. If you really care about Amarin employees, then re-issue to these hard-working employees the equity that you clearly do not deserve.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>This latest act by the Amarin board is a new low which is saying something given the shameful behavior undertaken by this board to date. We believe now more than ever that Amarin will never see its true potential without major change. Sarissa
        will work tirelessly to hold bad actors on the Amarin board accountable and to overhaul the board for the benefit of shareholders.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Additional Information</div>
      <div><br>
      </div>
      <div>Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of
        Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;). Shareholders are advised to read the definitive proxy statement and other
        relevant documents related to the General Meeting as they contain important information.</div>
      <div><br>
      </div>
      <div>The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available
        at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).</div>
      <div><br>
      </div>
      <div>#FreeAmarin</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z4b88ab5d331a4ddb8c3b6e35524834bd">

            <tr>
              <td style="width: 10%; text-align: left; vertical-align: top;">
                <div>Contact:</div>
              </td>
              <td style="width: 90%;">
                <div>Dayna Packes<br>
                  Sarissa Capital Management LP<br>
                  info@sarissacap.com</div>
              </td>
            </tr>

        </table>
      </div>
      <br>
    </div>
    <div>&#160;</div>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
